The New England journal of medicine
-
Comment Letter
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
-
Randomized Controlled Trial
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer. ⋯ Dostarlimab plus carboplatin-paclitaxel significantly increased progression-free survival among patients with primary advanced or recurrent endometrial cancer, with a substantial benefit in the dMMR-MSI-H population. (Funded by GSK; RUBY ClinicalTrials.gov number, NCT03981796.).